Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Paradol is a bioactive phenolic compound found in the Zingiberaceae family, particularly in ginger (*Zingiber officinale*) and grains of paradise (*Aframomum melegueta*). It is a metabolite of 6-shogaol and is known for its pungent properties. Research indicates that 6-paradol possesses significant anti-inflammatory, antioxidant, and cytoprotective activities. Its mechanism of action involves the suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), the inhibition of enzymes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and the reduction of oxidative stress markers including myeloperoxidase (MPO) and malondialdehyde (MDA). Preclinical studies have demonstrated its efficacy in animal models of ulcerative colitis, neuroinflammation, and metabolic disorders, suggesting its potential as a therapeutic agent for inflammatory bowel disease and other chronic inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-paradol.